silk-20201110

0001397702-20-000042.txt : 20201110 0001397702-20-000042.hdr.sgml : 20201110 20201110160727 ACCESSION NUMBER: 0001397702-20-000042 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20201110 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Silk Road Medical Inc CENTRAL INDEX KEY: 0001397702 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 208777622 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38847 FILM NUMBER: 201301158 BUSINESS ADDRESS: STREET 1: 1213 INNSBRUCK DR. CITY: SUNNYVALE STATE: CA ZIP: 94089-2918 BUSINESS PHONE: 6505669060 MAIL ADDRESS: STREET 1: 1213 INNSBRUCK DR. CITY: SUNNYVALE STATE: CA ZIP: 94089-2918 8-K 1 silk-20201110.htm 8-K silk-20201110

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 10, 2020

SILK ROAD MEDICAL, INC.

(Exact name of Registrant as specified in its charter)


Delaware	001-38847	20-8777622
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)

1213 Innsbruck Drive

Sunnyvale, California 94089

(Address of principal executive office) (Zip Code)

(408) 720-9002

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, Par Value $0.001 Per Share	SILK	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2) of this chapter

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 10, 2020, Silk Road Medical, Inc. issued a press release regarding its financial results for the quarter ended September 30, 2020. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

This information is intended to be furnished under Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.						Description
99.1						Press Release of Silk Road Medical, Inc. issued on November 1 0 , 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	SILK ROAD MEDICAL, INC.

Date: November 10, 2020	By:	/s/ Erica J. Rogers
		Erica J. Rogers
		Chief Executive Officer

EX-99.1 2 silkq32020earningspressrel.htm EX-99.1 Document

Silk Road Medical Reports Third Quarter 2020 Financial Results

SUNNYVALE, Calif. – November 10, 2020 – Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2020.

“We had a strong third quarter in which our revenues grew 18% year over year. Our patient first culture and unwavering commitment to reduce stroke risk are evidenced by our recent milestone of 25,000 cumulative procedures,” said Erica Rogers, President and Chief Executive Officer of Silk Road Medical. “We are continuing to make meaningful investments in our team and our strategic priorities, paving the way for the bright future ahead of us.”

Third Quarter 2020 Financial Results

Revenue for the third quarter of 2020 was $20.1 million, an increase of $3.0 million or 18%, compared to the third quarter of 2019.

Gross profit for the third quarter of 2020 was $14.6 million compared to $12.9 million for the third quarter of 2019. Gross margin for the third quarter of 2020 declined to 73% compared to 76% in the third quarter of 2019, driven by unfavorable production variances as a result of temporarily idled manufacturing operations early in the quarter related to COVID-19 and previously announced investments in manufacturing engineering and infrastructure projects.

Operating expenses were $23.9 million for the third quarter of 2020, compared to $20.3 million in the corresponding prior year period, which represents an increase of 18%. The increase was driven by selling, general and administrative expenses related to growth in personnel and product development initiatives and partially offset by the continued reduction in travel, tradeshow and other expenses due to COVID-19.

Net loss was $10.3 million in the third quarter of 2020, or a loss of $0.31 per share, as compared to a loss of $8.0 million, or $0.26 per share, in the corresponding period of the prior year.

On October 29, 2020, the Company refinanced its long-term debt at a lower cost of capital with a $50.0 million loan facility.

Cash, cash equivalents, and short-term investments were $153.9 million as of September 30, 2020.

2020 Financial Guidance

Silk Road Medical is not providing annual guidance for 2020 given the continued uncertainty related to the COVID-19 pandemic.

Conference Call

Silk Road Medical will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 10, 2020 to discuss its third quarter 2020 financial results. The call may be accessed through an operator by calling (844) 883-3861 for domestic callers and (574) 990-9820 for international callers using conference ID: 3146919. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.

About Silk Road Medical

Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at

risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the impact of COVID-19 on our business, financial guidance, progress made on achieving our corporate goals, and the overall strength of our business and culture. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our filing made with the Securities and Exchange Commission in Silk Road’s Quarterly Report on Form 10-Q filing made with the Securities and Exchange Commission on August 13, 2020. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Silk Road Medical disclaims any obligation to update these forward-looking statements.

Investors:

Lynn Lewis or Caroline Paul

Gilmartin Group

investors@silkroadmed.com

Media:

Michael Fanucchi

Silk Road Medical

mfanucchi@silkroadmed.com

SILK ROAD MEDICAL, INC.

Statements of Operations Data

(Unaudited, in thousands, except share and per share data)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019


Revenue	$	20,067	$	17,026	$	54,093	$	44,721
Cost of goods sold	5,488		4,170		16,074		11,206
Gross profit	14,579		12,856		38,019		33,515
Operating expenses:
Research and development	4,711		3,187		11,232		9,008
Selling, general and administrative	19,202		17,064		54,652		45,064
Total operating expenses	23,913		20,251		65,884		54,072
Loss from operations	(9,334)		(7,395)		(27,865)		(20,557)
Interest income	249		565		951		1,215
Interest expense	(1,215)		(1,176)		(3,620)		(3,736)
Remeasurement of warrant liability and other income (expense), net	(15)		(1)		(74)		(21,046)

Net loss	(10,315)		(8,007)		(30,608)		(44,124)

Other comprehensive loss:
Unrealized gain (loss) on investments, net	(164)		—		150		—
Net change in other comprehensive loss	(164)		—		150		—

Net loss and comprehensive loss	$	(10,479)	$	(8,007)	$	(30,458)	$	(44,124)


Net loss per share, basic and diluted	$	(0.31)	$	(0.26)	$	(0.94)	$	(2.18)

Weighted average common shares used to compute net loss per share, basic and diluted	33,757,599		30,764,354		32,597,007		20,249,580

SILK ROAD MEDICAL, INC.

Balance Sheets Data

(Unaudited, in thousands)


	September 30, 2020		December 31, 2019

Assets
Current assets
Cash and cash equivalents	$	62,468	$	39,181
Short-term investments	91,442		51,508
Accounts receivable, net	9,398		8,601
Inventories	10,946		10,322
Prepaid expenses and other current assets	3,443		2,878
Total current assets	177,697		112,490
Long-term investments	—		18,224
Property and equipment, net	2,824		2,734
Restricted cash	310		310
Other non-current assets	2,997		3,644
Total assets	$	183,828	$	137,402
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$	2,046	$	1,898
Accrued liabilities	13,008		15,034
Total current liabilities	15,054		16,932
Long-term debt	45,160		44,879
Other liabilities	3,876		3,700
Total liabilities	64,090		65,511

Stockholders' equity
Preferred stock, $0.001 par value	—		—
Common stock, $0.001 par value	34		31
Additional paid-in capital	341,687		263,384
Accumulated other comprehensive income	152		2
Accumulated deficit	(222,135)		(191,526)
Total stockholders' equity	119,738		71,891
Total liabilities and stockholders' equity	$	183,828	$	137,402

EX-101.SCH 3 silk-20201110.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 silk-20201110_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 silk-20201110_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 silk-20201110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One City Area Code City Area Code Cover page. Cover [Abstract] Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 silk-20201110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 silkroadmedical_logoxrgb00.jpg GRAPHIC begin 644 silkroadmedical_logoxrgb00.jpg MB5!.1PT*&@H -24A$4@ !BL &3" 8 !9!B$O "7!(67, "XC M N(P%XI3]V @ $E$051XG.S=3X@DZ?KH]?@=C\*]$-:<&]=U]4%P)53- M[H)HY8!P-V+E[.1N*B-)4M!%5X.X[6JW"EWM0B1),JK-"YDL14$0 MINHN=.&?4P4J;H)?EW'AQQ5EY.UYHB>[(K,J_\2?]WG>[P>*.2>SYYS.S,J( M]WV??W_UZZ^_1@ " < U'X^^B*#I^]@:L>NRYQ?,'9M-)Y3$ #@-00K M ,"PI4#$FV<_[O&CAE_YK?SS+HJBS^4_"6@ #@.8(5 &#$<#0^ MEL#$\L^!IZ_N48(77W]FT\E#Y4\! @" 0K&E"D29FQ5.K5\/_R(#]?_WN< MY2SD 0#80I$FQY))O.K>O.#^"D";X6C+4P$*W90I$EOJ7]K&9AHHX1ZG2=9T$?/RZO=/^,L_[SFWP, P+PB M3091%/5ED;O)(9Z[K\[=3YSE\\JS -"AX6C\9NF:=AK 9_%8!B[<=7DVG;"W M 0# */9N(%CQ JF0*,NG>Q*4.%S_;WCM=JDZ@^CC#HHTN5#V5U[$6=Y:+V#Y MO@PJ3_BMU?<(*K]'[EIY57D4WBO2Q"41G,O//EG&[I#,_0Y<=AG\E\-);=?8 M$#RO?(VDC0V'J:B5M'8J-^]:]R-UN2D/)?BNH6MR?RZ[*I09P,]]7DHN_$RU M$ !\R]K>#?LA6+%$RHN62ZBM;P2>EDNLJ<)X69$FVKXL'^(L;^U@6"J.?JX\ MX;=6WR.H_![=QEF^JN04'BO2Q"UR+VINA>(6ON==9>M(FQ=MUUA4!PLO.*C" MII8J*,X)4*QU(T$+$@O0./E.+I\7[--9X7$ID?!.6IZQ%P<0'(M[-^PGZ&"% M9(+WMBPOLNY^*7BQ('CQ.X(5+R-8@4T0K$"3)"/'+4A/&OR_<0=C@[;OCP0K M3"JK7N_HRX]EP]%X(%4435[+K'DJ,RD9T(TZM5S5=+M4-<3OL5'#T9B,X?8] MKJB$C9:229;_,TDE+6EI[W8M00O.-A4)+EBQ5#TQZ'#&A";E@LD%+H*^8!.L M>!G!"FR"8 6:(O?W>4O9QRZPWVMST4NP(ABW2WWYV2@'9#@:E^T/!E11[.U6 M@A9D4V)G$C0\[_#,P"5'7/%[; _!"C7*3B0/2\DE#ZS/ZF%][X;]!!&LD J* M/@&*O3W*Q>0JQ, %P8J7$:S )@A6H FRV%VT7"'Y)(O>5NZ'!"N"]%0&+NC- M;Y>TE;F0O0I5WO5R>Y<+6D1A&Q*DN/ H:/BEE0E!"SL(5IAP*\&+LCIV5=4& MUNAH[T; 0A'3P0J9($\)=3/*H357H0SJ)ECQ,H(5V 3!"M2M2!-WF/ _1E'T MMSMXP(6_ON#M1?DJBB*-+DHTL3]\F4$*AKC#H?>1U'TER)- M%A(8 @"@;?]31X&*2*HUR71$6TYE;?O7P]'X2@)84,:U>W*?GUM#$ZAHC=NW M9,/1^$&RYH%O#$=C%SC\Q?.S _=W^\MP-#ZO/ .@:X=R3\_D>WKGKBL2!(60 M&157'5:2ND21?UQY%-XQ4UDAK9[(3NK6DV2CF*RVH++B95168!-45J!.19K< M>=+>L?%K"9456..Q7'M1;>&WI9D4Y[1[ZMRM5%HL G\?@B??RRL)!FMR(U46 M7/<5HK(B.&4[]5)]KW7\=93F*[Q]175K@#4I?93W:2%PZ6 MJBVN)( $ $#MBC3Y3SV:0_6>>QXZXC+Y/KJR=JFVX/?00\/1N"]]K=\3J/"" M.Z#X6;XSWX7^9H1*/ON%PD!%)'_G!;^_@ J' M!"W\X3Z'X6CL#D-_\FA8+WYW)H$^6D,%9BE0X4O2PRZ."%@ ZAQ)JRAW[[D, M;+WFVU[I/RS2I%]Y%%Y0%ZQP/<9^#)PA:>$#ZRM^15.6] YEGL>#[$@8C@8H2 0M IX.E:@OS<\AD_^;C M>N@_DX'?\(RJ8$61)N.'"<-#"UWMK[.X),O@;'E$1 MK'"'$S)$DT6_?E\VSD6:7'!! !L2NX9"\_7 ;02@6_*>6)W,CLOSE,PD^,H>SN>N. <$+/SC?;#"'6I' M4?2+T45%J+YNG)EG 0!XC9) A7- *3$\Y>8E_$2KFV:X@VUWN" MZDBLTN]4 M GQ5JIC-5PYG?D>?5^<+P-5BQ54[RO/ DK#I?F M61#%! "L!BMD-@75%.%PV4L/3.(' #PGBT:?2X>?(ZL1OBM; MW3"4=4]R@&"M_SV^]5%:TJD*JG$ZD@ 6##@8'*6$U[HS/I[H..>16L M<-GU+LM>9E,@+%\NPE19 !*DKR@+5N9>QBT.#&2L=<)UY[!K5UI^Q0$=Q\B MN*>4#*P-:8X,!VV /9HK8[4E\"59(C^>%LNQ)U(\J"P! )(M$ MCQ<6?!<8U)' MQAS";GD1K) ARY10HU166=!S$P ")(O#3.DK)\L:&KVG+=3K9)#V'?,I@G4@ M%18D52DAA_:' ;YT M" 7:=29<%A>K,6!"RZTWFP0C(G?V9SCQ7>NB'K19IH M[Z!B$?BA)U8C8.&WT#..3X>C,1T* /O. M7(M*CUMY:D_D.@IP]E'G.@E6%&G"4#KL(I/?'0" /9=&LI8_5QX!]/F2*!+Z M0>Q2H()VM5B'@(6'Y)#^)/3W@>H*(!@^5\9:2.0ZY2RR7:T'*R0[GJ%TV-59 MD2:480& (46:7!I:&S!O Y8$>Q!+H );(&#AG]"K*DK\7@+A\#5@8:7J_(QN M+^UI-5C!C K4Y(2^<0!@@ZP-WAKZ. E6P)K@#F()5& '!"S\PF?Q&P9M V$Y M\#!@86EOE!&P:$=KP0H"%:A9.7B;@ 4 *%6D2=_8VN QSG)F5L"BRU"&;DO/ MYSF!"NR @(4'Y'">[^_O^)T$PN);P,):(M=ED29!K(F[U$JP0C[(R\H3P'XN MXBRG-S@ *"1K VN]/^>51P ;?,S4JYT$*ABFC7UD9+)WCL/Y;YUZ/'@70#.\ M6;?)F=UUY0F]#J33RQM#K\D[C07YK11 M64&@ G4C4 $ 2LFBSF*+E>LXRQ\JCP*V'%J=RS(1&PB+/SO MB/: [9'O,O-FUB.0 X2K\P!ZG.5W411]J#RAWYDDZJ-&C00KEEH\ '4A4 $ MBA5I5*.F*BNNF%.!&A&H #%9/'VWN!G^$\X'$' #@P,3+0X M/P?^^K"C2Q-T M3RM/ +LA4 $ BLFB+3/X&?Y-%$7_> <+EUFR:#L!88W[+!1T>I)>URWAT0S _SZ:3N\J? M?($<@KIK_QOY.99_'JW_MX+R=C@:+V;3"7-2:B2_=_R.;>Z1-@ M (A !0 H)H&*A='[U[\59_E6!WA +ZT@YI-)]YGCDO[I] /-F_E&NU^[NHZ MJ'@IN"$9G#T)8(3<,OA2 A8<8-2'UD;;86X%@$@.U>>OG$JLK B]_=.3!" 6$IAP/W=U1M+D\*?,6NLM_?,[0YLN A4 H-^5 MT<- =X\B(Q98[=P-;9Q-)\\3=+P1^,9, A_E(G_Q_'GY@I-&!',+ZO"D++;GJQ@6/?6P[)'^GN02Y>O)[TS?8 M.G 5UPYJ+@$<[">4WYFZ#6B'!T"\EXJ_SNY)<9:?2W+V6>5)W3:=]#7,1W ')+/I9"!)5^\"&=S-L.UZ<&_>CU=62%5%=87_NX+?4]*[DF M4 $ RLDB[*/!S_&>PY"=?= PPV 7LJ$KAPDO5[:&/@LADC6G5SUZY?.R?CCL M#O@O-+=VD?94ES+782"?F=4642>TXMF/'+9SS=W=.>L; ,*7%H4]Z2)C[=J> M287%VME>^%8=;: LW^#<\#E7I6"F1%=>B_LYE[91 _GIJGR60 4 *"?W$XOE MK2Y0T:MS_A1LD$/5V@N,?LAH/V_?1Y#P$LZ;Q%H=MS20+T<(+0N7?2K4.S,IDDDFK8\B>DM=DFW#WWN,MUA3NGE(XPUO:7 M[K7,W=Z9_>7K]JVLL+:P>I)*BN">C0H)S"WT;/<0(5 *"<#$*[,CKOE"A@B?&TWT>>Y$-KL^?(?.#5ZC7&+5P)/WMW%R:'(A08LK8Q5+ M;L#X)=45VY&*&P9K[V^P7!T(K''G6;7DKE;^KLOZK&SG&6I5;,F+(+H$+-S? M(ZL\J=OA4H4%]_T7[#Q@6PXH^I4G]'(MGXY#G](N0[K=HN7/,DR\"00J $ Y M60=8["D:R7V*0 5J)4.$^[+&N@G@W>V\FL%H586;!>-+(*A5[C6[URX#Q*TX MH!7/3BR=0W3IE$';")VLSZYFT\FYW&/^%$71CW(>]A3@V_/>A^N"G!FFE2?T M.S+:/KE6.P$.3'ZP.K1^&_(>_&#H$(E@Q1;DNA)"A5I; M"/P 2UREFVN/-IM.7 7C=TN!BY!XL=:0/9G%]_ZL2!/VFR_8)UAAH4>D6^#^ M&&=Y$O^=21H4=>&FD % !A0I,EE"^T"NW =>H4EVB.9?,?2"]IJYE[7^P4K M/>W=&OR-D38T;+&0+7TLV)]:0 MPR,+WQT.C#<@UQ,+04C?<)T!MN!F7,A0;LN5%B<>55=\EN2$Q\J3^ET6:7)L M\'7M9==@A>:;&8&*/4EKJ$V&V_%> X 1LHBR6"%7WJO(6D;GY&#ZG;%/HO5@ MQ7 T/C8P4^<=@8K-R7NE/6!!.Y[7,5^A&:[ERW<67QC0E++20I)Y;XV^T=[< MEV2OUC<8''*SU1;2P0ABZV"%O(&:%_\##L_K(546ZX;;$:@ "/DWK\P-*BV M1* "WI&V4*FA3Z:+PT7MA[[7\GN +4C 0G.;B%,/AM)[2P[3+<[+\@6!(& ' M4AW;,SJ#S*O[DIPO6JQ"='OL>9$F!(W%+I45FG\Q/M".J%YNEH64ORUO# A4 M ( 1LFB:&PQ4.'WN5?"1M!>P$K XZ* 5E.9#-UH_[4?[# L.C-?C>]$L*GN M/4B2@94Y2LN\FJDD>S=+23VE(TD.#%ZT8[!"ZP+J5BH!4+.E_G'7!"H P)RY M@78JJZ02< >\9"Q@T=K^00(C6H.K]P0J]B.#R#6WB># >#W>FV8=20L] #N: M32=EYK^EME!]W]K$Q5E^M4%;>HV.BC2QV'9Y:Z%45CR1B=$L%["(L]R]Q\<$ M*@# !EDLG1C\.#_((A?PF@0L+ S=;C/926MBU9/1U@:M'')@7"7O M"8.UF\>9"; GF671,[)^BR0!Q+M[JB2C6WF/EYT5:1)\*]"M@A4R7%-CIM*E M&PI=>12UXWT& !N*-+DPVAOZFDI+:&*@#W\DK:#:.H#5>DC=EZH U& VG2P4 M9UUR8%Q%544[^-T#:B+K-RN'Z5Y>@R5AVN)P\[=%F@1]/=ZVLD)CML^C"U94 M'@4 "O)XNC]JN>4NY=%+:"-YK8VI<:#"(I;0'V2PW74:#:=7"@]Q&!NQ1)I M/$[T@X76&:=!-3$4,#BR*=!V\_T#_E/J71/BQ5H)6UMM&<6M_']TWB@^>C;\$IC-!Z\'GI\*-0%S7-H-")8 M =3(4,#"U^J*5>;2X2@XUH,5C_2D!@!@,[(8FAM\N]SBM4_R C23 M^16:2]W;F'^C,2!Y0?NGYDB@3V,[*"H)?D<+J':=$"P#ZF6DI:>W]R7# 0L7 MJ%\4:>+5@/,V;!NL.*H\XC<"%0 ;$ 607.#V8M?AM8R4PE&J,YX'8[&C043 ME [@O94@%)IUJ? @V#%[]]K;6<0%E!= =2O)]646AVV.']L:W&6WQF]=@49 ML-@X6*&T5Q:+?P 7B&+GX7"@[Y-#&3Q"J@G6>*:6PDTN02UD\H5 M;=GY;50B::#YX$ESAB_!"J!FJT59[E+O$LK3^AW9+3[P5K;5%9H M*P6\(8L2 ("-7!G-7$QET0I8HOF N\E-KK9@Q2U#M=LC%2RJ#H^;K$121/.A MN>:_N\N@IKH'J-EL.G$)5.\4OZ_>7]=D%,"GRA/ZG11I$DQ"ON5@!8M_ !> M(8N>TY?_E$K7S*V"16 A=7*"JHJ !8018U"\5]H-=QB] !@0H$1.N! M=Q,;*TV;M4<9L(D.2,:[ID,+TYF3+S 1K%CSWS4Y;*@:#@B>!#,U)H\UTM*S M*7&6WTF Q5K PNWEYT6:F&S7MU&P0N&+I[(" (!GY'Y^93!0$4E%!0> "(8< M>&ML!=7$OD+3QIFY>MW3]!D$=U \'(W[[I"\\H0.M]+>Y2L#@[:IK@":H[*Z M0EO5G^P1+5[+#J7"PES 8M/*"FV+)+(J 0"H6FC+AME02J "@=*8H%/KOD)A MFQR"%=TC6.$W2U45)4*_(XOMG4VV M@>+ @" ;Q5ID3S09*KQNU7'@50%XW7!Y6!=-DS7E>>T.],]OIF6)U9 0 1)$F;A%\ M9O#]N(ZSW.*@<&!3&H,5=6]PFQC8W12"2QZ03-9;+7_?P&8&6*RJB*0UE)K? MN15H!04T1&E;3[7WI3C+W7WFIO*$?BY@H?D>^@V"%0 &":+EK<&7^&-+#:! M8"G-TJ][9HZF#3-5%?[0]%EH"LCM2_.A^-I@Q8;/^^QH.!J']'L(M$U;*RBM MVKZ0"- M8(4_-%6Y!%%9(?-GM!Z W4MV]$OFRJ_75%< S5$7S%0X,^RK.,L_R]P-;14M MF[@JTD3]NF'38(6F@4H,UP8 !$\6*19G.;B-?D\6F0!H+:3F<)-Y%5[1]%F$ MT@9*BC3Y3@YBZFZWTC4"%8 !=67C*Z("GM 4K M3%3]R=XRK3RAWY'F]J,$*P L&4NBQ-KTCC+::$"5(5<::0I&XZ@DG_4?"92 M>6"9Y<':^_YYGYPR:!MHC+9]CIG[4ISE[KK\H?*$?D=%FJB\YY@,5FCOS04 MP"YD,6(Q _.#+"(!0"N"%?YAR+8'AJ/QL>(DB\<=9M%H7\_0"@IHP 9#^GUC M:L\99_F%JY2K/*'?69$F%]I>Q:;!"GJG 0#@,5F$:.[WO,ZU+!X!X#E-E16T M@?(/GXD?0JJJ*.>E:#X0(U@!-.>6][8[<98/C'X&[XLT477MMMH&RFSF"0 MS\GBXWWE"?WN9=$( *HIS)@T3]EG8G$ :$GS'(1=JR0V'!"L %"L2!-WS\L,?H;WQ@]G@+J$7%&LY;4_ M51Z!+Q[Y)+HS'(U=0L*!TK_^S6PZV:DZ9S:=S)7_[I%( C2#BK^.Q5G^60(6 M%M=N'_] MMAJL.&3(-@# ,EEDS!5G)*[C%H4]620",&C7;&3%"+SZ2\O!D+F#X>%H_$;Q M@-8GJ8[8!X.V 3RG;7UD-F@99_F=T>NAIDGG !L0A85IP;?K&M9# +8G,:#(DV;\+I8G"UD!945'1B.QGW% MU:'W=64_SZ:3*^4]T4D0!>K'?N33@9O:@#AT+=T'S/KZNJHJ0Y4:// MH&V@=K2"\M.YT82;CW+&X)5M@A4:%W(G5%< "R0141F\,.\)S,/V)G& _NZ M-N&:#L@X>/#4;#I1DY!GI>6.#'2-+;H " 241!5-;66B'ZU$#K)LW!B@-F MA0*UT[1F"&9N6ISEGR5)R&+ (BO2Q*LUAO7*BJB!S < %HEBP>+][-'M^B3 MQ1^ [6E,R@GNX)Z!F:B)E0QVS545\]ET4NN:10)FF@^_J(P%$ 39LPZ4M^]; M9^%3P&*;8(761?:1KSVX !XC2P:%I*]9HE;Y/4)5 "[D9[O&J\+'-S#-X]\ M(JVB!525YH24$ZF6 5 /YEQY+,[R.TD6LA:P<'N*JR)-O$B,""%8X5SX5M(" M ,!K9+%P93!0$4E%A=:J3< '6EMOU+6GT+*VMYA]9PT!M)8,1^.>XL':CPVV M#:N[M53;2 X% A7BW!K9PUJ\[AU)A47GG^G&P8HXRS5']]PAS]R7"!$ !M: MR*+!FI1 !; WE<&*V712UYY"R[J>:QWJ8F$6(U45*TAKJ>OJ,VHPMP((5Y") MX7&6NX3"=Y4G]#ORH=IOF\J*2'F)[*$O$2( %Y3I,F5T4#%.UG< =C1<#0> M**VXHMT.?$0[PA9(]NV9XI?0]-I%\]KH4%H3 M@?20Y*Q%E^J3S0O,Z9G$5T M9MM@A?8OC3: +H.V@1HT?:U!O>(L=]>^&X-OJPM8='9=WS9886'0"P$+ ("W9%'P MUN G="N+.0![D)[O)TK?PQ"'1C(/ ?B-YC5 6QFFFA,Z3AFT#2!0[OYV;_"E M9T6:=%(U%UIE1]KR4'TIVHU22A;2LKG-O* M([J]+])D094% * KTIIPH71@[DL(5 #UTAS0M-C/%S9HZ1Z@,GM5!FMKSKAO MNS63]D';OP2K-!>FKC*B5197#++ @#0 M)L.!"JQJ.QA?*JPE"G%#&ZUKG%NI=FB-M)S2G)G+?#( P9*. M1*G!UW_4YEI^EV"%Y8W&6YEE<4'0 @#0DKGB/LXO28VUCP0Z(_W>WRO_!"PF M/&V"[$B$CL':>OY_ZW FU30 $*0XR]TU_(/!UWY4I$DK]Z>M@Q62(6EQ:$CI M0#:#+FAQU79?+@! ..1FK[;__ L^R2(-P)[DT$?[0?]CV]G)'B%8@6 -1^,W MBMZ*-!E0;0$ J(OP<2W-4\ M*Y1U((#@Q5D^,#CW.9+9SXU63>X:K @M6]*UY\BB*/IK&<9]SD!N ,"NY.:N MO:7+*O>R* -0@^%H;*7ZBDHK>&LVG="RL#F:UP1=5S=HOFX>2?M" +MAYI\= MKM+LWN#KRHHTZ54>K.8') M%\19_ED"%IJOY^O,FTKDW[6R(C+01[$.;O%U*MFQ/TOEQ6>IOKB2($:?*@P M0/1[H,)B!J=;?/5E,09@3X8"%5$3V<'2!Q\(C;;$.,US"SJO:IA-)Y^5M] C M6 &$@:3M5\19_B!)?=8"%NY,?-%$XOX?*X]L[DHJ#%#]L$Z>E^P7:1))-OC2@DGS_># 5==T.*0< +SA.A1)*^B?C'TJ9<"B5^?9]L[!"O>7 M*-+DVNAPT*8)(CQ(.VV #*2:!B86!([BKGW*^ _0&KB4[.&2AOWZ$27-6O3?7+=>*:C@:/RI>/PZ8600 OXFSW+5-2@VVA#Z2 M:WUM%97[5%9$!C._NK1--<8#&:P H,J5L0/(4AIG.9M08$_#T;@OUPEKE5?! MMXUE7@<"I3E8X=NZYE)Q1XL3%XB?32><70# ;P&+*VD-_=;8^W'JQB'$65[+ M_7^O8(64L=P^/V1'K5ZKQOC:3LK]YSC++?9"!P"UW$U;>2N$=:X)5 #[D;9/ M5J\1MQS4 ^&1X*O62H#'V73BVWY:>_MM=W!U47D4 (59_FY=%ZPEOQ_5J2) M&W6P=[+2OI45D=QX?JX\BC:4 8RO&]QGU1AW$LQ84(T! .V3OI06*Q"OZ\J: M $(U'(W/91UMK9JBQ.$4$"8&:]?(M:0:CL::VV\3K " *K%CD2:? M]TUJ_$/ED2U))O_MOO\[J%59B>'*BMY+,.DO19K\6J2)&WQRZ0[0I/0( - M"518ZT?IW,OB"L .W,#1X6C\()FR5@,5MQYF)P,ON7_A.6Q(JL4T)VGX6C$Z MKSRBQZ%4VP A RC[AE=?V3[GC?745D1R:'%+Y5'X:-O9F,LM9.ZDPJ,19T3 MW $@1')SMMBKW57N];A/ -N1 [QSR3"U.&C_.;)HH0WWM7IHKKJ\\76VPFPZ MF2L?M-U7'G !@-JY/;4D."X,)C"Y1'EW;K!32]B]*RLBF5WA6D)4GH 6917& M3U$4_;7K,2;5%WWIHP8 V%"1)F^,+CB>W&:30 6P&1>@D"H*=T#SUU+M&D*@ M@JH*(%R:*R]]/TS7/"?L3(+V ( ED[VV)>XLY&K7,^6Z*BLB69CT#9>S MA^1(?KY,IR_2Y$8.WN;,O0" ]>1F/#=Z+]PY,P((Q7 T[LF&H[=* [)/L^G$]V# E02]M1H8K3H&@+VX/7:1)N<&6T@?+558;)7P6%NP M0LI7+J3_+FPYE1\W*.5>%DH$+@"@:F%P2):3$JA Z"0K=+G_JOO/Y6-OC'[W MM_7)US8J !JGN:K"^ZH%=VT=CL:WB@/AYP0K@(TME IN)CO.^4= "PHTN3*Z&'E.Z[SV-'[ MX6C,1BL<3\RJ ,(DP5S-0Y2UK'.N%)^UN$';Q[/IA.07 %A!SM1=$M19]5G5 MSHHT^1QG^<9)#;7,K'AF8+#7%E8[E2GO7ZIJI$\[ 3'S?DQN*APKMVBJ?(H M %0-9M,),VV ,&EN!WVOY0!=6E5I/FO17'T# (V+L]R=J=\8?*??RC#QC=0> MK)#60/2J#0*A6 Y:D#T!P!RYR5K,)'8;]YXLD@#@-7W: M/P%!TUQ5,==V_9*659HS;@EN \ K9"_>-SAFP06M%Z\EMS<6K!!]HZ4KV)P+ M6CP4:4)_2@!F2!!VH;@_\SH$*@!LX\-L.EGPC@%!TWSXK&6P]G.:JRM.I!H' M /"".,OOC%:CN3.4^4N)[8T&*^2P@X';<+^('XLTN=NDW < ?&8X4.'T95$$ M *]QNA1\7!5NV5O20R L &XBQW]ZG4X'MU]-*]K.G* MBC(2U"-@ ?EE_*5($S:V #2;*^[-_))4%D, \)I[6GD 4'X=4%N=(*VKKBM/ MZ,'] P V%&>YJP+\8/#].G&C RJ/MA&LB A8H.J]5%E0_@E %;F9GAC\U#[) M(@@ 7O-EH#9S*H"P22L?S6NBM1F=2FA>MQT,1V,&;0/ AN(LOU >I%[G;%5" M>RO!BHB !:I<5K(+6+!( :""S-XY,_AI7<=93CD^@$U\F6LC UX!A$US=KQK M8_=0>501:6'UJ/@E4%T! %N(LWQ@="ZT2VC_YI[06K B^C9@P=!M1-+?]">& M;P/PG=P\/QK\H.YET0, FQ@0J @&*S=/4(/ M.BP P);B+'^0I,-_8NR]^^>B*/KOBS0Y["1849+6$RES+"#<@#8"%@!\\K>C M*/IG#'XB_U<41:I[-0-HA5NC_TB@ D!I.!J[O=JIXC?DLO*(;IJOSX?#T9@J M7P#8GMO+_XW!]^V?C:+H[W4:K(A^"UALG ,LT5U7<:A^L_9QEBRB*_@6#[]N_'V?Y M/^P\6!%].\?B4^5)A(B !0!OQ%G^'T11])\;_$1.F1<$8(U["50P3!O S9+08J;F2F]5?>!2M* M<99?1%%T[*(KE2<1DB/:E #P@:L -#QCZ;)(D^/*HP!"X1*$?IA-)Q=\X@!6 MD58]F@])K W6?D[SZSL:CL:L0P%@C2)-7 5:MOI9U>Y7)4)X&ZR(?CL8>I#H MRO=2DHXPT:8$@! .\[RGLRS(&@1)M>FI!?ZFP"@ M>^Z>)!46UKB Q16S@H!@N$.M'V?329^V3P VH/DPV7I51237<U,WM0_JK A61EF!%2>99N .B/],>*DAS#M$ ^$ "%JG!#X-9 M04 8KJ6:PNJP60 UDA8]1XK?TU#:"FM^G0?#T;C2"@0 0B7GGW.#@8I(*BK6 M5CRJ"E:4EMI#_4D&<3]6_A L.@AHH0G Y*XOY M4;+$K/41Q[=.9; , '0NSO)+HY5^;E:0^98)0$#:]U^A M59!I7K^=#$?C-Y5' 2 PDCQH,5#Q09(^7Z0Z6+$LSO*Y5%N\D=8<-Y4_!"OH MJ0[ &W+OL7C/>5ND"1EN@&YED,*U?*)B"L#6I#6/UA84CP&VN]-^K6?M"2!H M19I#.OYJJ>*"5E%V'(0P) V *@-I MKV)-1C4;H!)!"@!UT7QX'-SU3UI>:4ZB(5@!(%B2+/C>X.N_E23/C9@+5CQ7 M5EQ(JZCOI;_X#>VBU',M2HY#?Q, ^,$%RMV0**/WEBNNMX :MRY1AR %@#I( M2YX3Q6]FJ-=!S:_[<#@:DR@#(#A%FKCSA,S@Z[[?MIVD^6#%,C? P_47EZJ+ M[Y:"%]=&,V*MH[H"@#<,!RQ<-=N"]GN MUP5Q:?$9:\6C=[S[1"N]+%P*MP8I(JBOHI(!0$:P(A.% A3.0(H&M!=4& M:E=QEC^XPR=I(7419[F+#+V1 =[?RQ#O#]).ZE;GJU3K1*IA , ;<99?R7W! MXC4W],T_X -:9 #U.N+]K&"PMF(2T-9\-J&Y!1D ;.K*Z!HD=3.D*X]NB&#% MGF0.QER"& ,)9+@@QI^B*/K!?4!R8'7+7(S&L) !X!UW7Y @MC5G19I<\!L' M=.K^TZGR1YT@6J( M].1:.4M!!J4J8.R_5 ":N""V7/.M94N\+]+D8=]% M"("='4BR!H%# $W0/*OB?C:=[-1VPAK7"FLX&E\J/F">545G1 JC$6SZHQOJ,:8R]45P#P5<_HM3R30 R ;IQ+]C,\1F8P ME-*\MV+.P;=V;L/A@3Y5A "L*=+$!6$_&GQI]W6M'ZBL\,@KU1C+%1CE/ZG& M^-V @ 4 '[EK>Y$F+D/QSN UVPT3[^TZ. O 7@ZDLH*L4[]QT 95AJ-Q3_%@ M[4CYX7P3+A5G[QY(E0^5O !,D&2_S."GZ0(5/3G7WAN5%4H\&_)]OJ(:HZS$ M> KT+3J0PT $ZTJ>L9O$:[3>2\2!,.XX!NG 5:74'K3X2HK2I-S0'0Z]ET M4LM!B172$DMSA2$B0!,D$#%R@1UY=P9QZ"N0$5$985^2]487W_AY0O0DX6F MQ:GRZ_3)I '@*U=](+TIK652'"Y56'! @&77"K(AW=KA;>5178*KKIA-)P_# MT;CR.&!&H[&=W+0KWGCX*HK+CC( 79#3_QO: Y\/OI^S^F0YF!%)&<95%@ 4$D" M%0NCR>3G3;2$I@V4<=(^RK6.>B/MHFX-OV):00'PG@M82,:Y-:=%FI#1"%6D M78B%8:P7E4< ;(HAZ+_3'*Q@#;*&W.LTKSV9S01 LTNC@8IW4$*P!X+\[R@=& Q5F1)FPHHY=HGQ:Y[;&\&* $G0XHT,Y;:F%_KG M"T"-<^4##]?)"%A $T/5%1S4^8D@$K30W&;GAE9X+Y,669H3%EE;(B2:*OZ8 M6;B&[(DM!BIN)/FR,00K A9G^85466C/)EQV* /& $_F=FC.7"=8NQG-[],I%80("+.4E),6]=;F5$:2;-EX M\)A@1>!9M/)G$]](]J#.E17 /">[($M!M%=DF5/SC :1; "R]F]-T;>#8(5 -2( ML_S.Z'7+'7I<%6E"9A"TL'#03W4%L#TM@?4F#P<8K!T "P9K;V8DDC,9" ]8IND\JY6V0+Z3Y#R+ M@8H/DE39*H(5J)#2'NT9"Y2' E ISG)W_;TU^.F]+=*$;#AH8*6ZHE]Y%, J MP28YR75"[6!MY2V-NJ2]XI7[&ZS3=%UNK360KXHT<7N',X,O[3K.\D[V100K ML%*HK "@6=_(#*'GLB)-V&#":X:J*\@X!C83Y-(B'!"KQ*2H!N M%+Y39+$!,"/.\G,C6=[/G15I0N8WO"0'.;<&/IW+X6AL[<"T(,DAWII;JEU(H/B 4OXG?:4)-F=&GQIGR0YTAL$*[ I6G4 0,?B+'<9 M9/<&/X?W19J0'0=?60BF'3",M%.]@%^[[T(\%-(^6)M]:;VTOY^L'X'N:*[, MVDJ1)N?* _WK7$M2I%<(5F!3&A,51=<6ZLNH(V M,*B#EOU"G=<@S8%+ A4UD_E,&KLHE A6P!I-"0Z=#V)N@R35?33XTNY]71,0 MK,!&9-"VML,Q@A4 S)'KL>LU_63PY2T(6,!35%=X1ME 1ZYK_@IJOR S.C0/ MUM; "HG>Q-+=Y[W/EN3\X6O$.P MM8\&X!0/=DEE#/8,#" M':;.BS1A&"V\0G4%]L1[[B\MP8JZ#A,T!RQOI0H -9/66@S:!OR@*<'!]#59 M A4+V:-:XLX0!KX&*B*"%=@2@PP!P!-QEM\9[4%_*!46'.[!-U17^$?+X1J5 M%?[2$JS8>Q\F@4K-&>@,UFZ6YA9;IP3B88BF@W&SP0K9BUX9#53TY"S!6P0K ML UM%R+:0 $P+Z B(EB!;<19KJT-5$B;#P"! MDH#%M<%7?U:D"0<3\(V5Z@H+KT,5#B#\(_,;M*AC'\9@;:PE+;8T!^0M5ALC M/-J22:QV7[DT&JAX)V<'WB-8 0" \'8[&%BI0-272 M4/'KGV ^$_F^:SYXH=JR'=H';=-R#]II^QWV=N;!KHHT;,YU_^Q==QUFN MYEY*L +;LK!!!P"+7$;9O<'7E1&P@&>L5"507=$N@A7^47,H)('2?6C..K^? M32?,3FS'7/J9:T5U!;33%JPP-;-"]IQO*T_H=R/)C6H0K P( XRUUF2T_1 MP-EM7!9I0K8IJPQ*BO\H>FSV"<@QV!M;$U:;VE>/VK^O4> I$VDMD-SU8?ADORF MN?)PG0^2M*@:P0I89FW + !L+<[RP;[#.3WUMD@3-J/HE*'JBA/%U16:*BM. MF%O1/6D1H^90:-?9+,/1N*]L6.MS!"NZ-5?\=S^0WW] "XV_KVIG5A1IXI)T MSBI/Z'<=9[F)1"J"%=A6$/U= <"8OO)AB>MD19J0J8RN45W1+6WK/:Y9W=/T M&>QS[]84*_6TE2-(%@ M!;9ET._>VOJ28 4VQF$0 .AE.&#A M@NB+(DUHK8(N45W1+4V58P0K.J3P4&C7RB'-V95/$@1&][1_#E170 .-ZP)U M74SD/--B(-SM[?NRUS>#8 6VH2U8H7K@#P#4+<[R.Z,'Q]D?W ( !)1$%4 M900LT"FJ*SJG:=-,+_5N:7OO=_W=/J\\H@>!"D](FQ?-<\$5D #C==K5<$* MV2/.#7:*<8&*7ISEYMHF$JS -JBL #EXBQW@=S4X.=X1-L(=,Q*=<5EY1'_ M:AT@ \ B&_GT<*7ZV:Q& )5"R4WQ?7 M&4@RHCD$*[ -;3=Z!FP#P IQEKN-YZ?J,^J=%&G"(03WL^F$/9Q'Y-ZFN84HU17PF<9$ER=EP[6O ME :$7I/&66XV48]@!392I,D;A5]P4SW; *!.<9:[[-)K@V_J69$FFMM?0#TGXH1NL]^$AK<%;%>DN2U[3= M]S=Q+7MXTPA68%/:O@P6#@H H T]HP&+K$@39BVA5;/IY+.AS&!MK0FT!2O< MH&T"%NU1UVICEWD5RH-@<[F&PC-2O:9YKK[UCY0G] M[D.YGA&LP*ND!92V\C1ZG0+ !N(L_RP!:8M!W@4!"W2 ZHIN:*RHO: ]2?.4 M5E5L/:]"X4R.YY@YY3?-@?@C^7X G9-[DL99%=;,GZ;(]5!&@>8[G(PS&!M-$8"\=>*WV'.G]"YX6A\J;P"SMN@I>SU MK@P&*B*IJ CJC+/58(4$*L[DE^;,N77.6'.@95:J*PZT5%W-II.YTO?\2+(M42^M&9:['-QK/H2] MV38X@VY(JRYM[?:6$:Q )Z2",E/^[M](,HZ/M%>LK/-.]N;!:258L29047*' M![1G$/6+P7]3@%@#W&6N\W"5047*+JXT3W$KJ$CV0PM%52S>,=!J8Y?#(,T5.>S;E)&679JK;PE6H!6& M A61C]=J.;?4WEIK%92&;[LRX%@D2:T D ;K 0KJ*YH!P&+'1EIM;'5[ZZT#CNL/*$'LUIT MTGQ><$C+/31M.!KW# 4J(M^NU0;.+==Q>^X>9YH-!2OV"%247/NA7UR5!;,L MVB-?>.T75'J> D"-XBR_DPH+:]R];LXZ TV3Z@HK0^O/E?3[UGX >D3 8CM& M,EAW&32M.?OREL':.BFO8(N45R/!<]**\&=#@8I=VA,V1I+-+ 6"2@0JEM0> MK*@A4+',M2*ZD_(>-,A(H"*BE!@ ZB#[^V1K%^ QDCVL)7JBC.J*UKC A9W#-U>3]JY6-C'N$'3VP;/-2?T/9%D MII[V:VSP/>%1'VG[=-? >6C7'CT;K#V7M9$U:9SE)- MJ2U8T5"@8MF)M(:Z MHL=T?8HT<;V'?S$2F>2P"0 :%&?YA:$#UV5G19K0-QM-LU)=$2FIKG#KPL?* M$_J4,RPX6'M&WI.?C.QC=OE.:9DAL\I<6N1!*0G":ZY@T_S]@2>6JBE^5CX_ M:!UOSMCDS/FD\H1^'R0I$$MJ"5:T$*A8YOY__D+08C^N?*I($Q>5_*CY=3S# M%QP &A9GN3L&;O8$7+@8IE M9=#"M8>R./BS,7(8\Z"\Q^ESUPRB 8#6] WT@U\E8TV!AE%=T:Y+Y4-@GSN3 M*HM@#]B6YE-8.K38Y3!(\R_&^E5O MG;DJU36:@S5451@AUUC-LT?Z5*MA$VZ],QR-+R7I]Z/1ED_+'GVX5DL2F;6! MY9$D_9$@]X*=@Q6>!"J6'Z,B330/'*O54I#B9Z,]WFX91@, [3(< ML/C2'Y[D!S3(TB&SAF01:]45I?:[[O7#-:V15IZ/2I^ M4;1AP1=RSW'5-I?2YNDODA!M\?[SDOMMYRC53?9@HZ,59_E!Y!M_X MX[9OAX) Q;(#^;N>%6GB'KZ1'J<+.6 Q1Z*/ _D)(>K[R.1\ .A.G.6NFC$U M6*)[),%P,N[0!$N# B]\+V5W!\+#T7A@N&W#B;2&NI9,?=7['&DO9G68YK*M M Q42E-)\<&8Q2Q:_!80_*GT?7-#]C202( !RCUG^ZM@A7* A6KG)9#I8LT>2H#%U$4W6EM(R1?Y)X^KZ7=YONGRJ.VG,DL MD5L)6J@Z&)8JG4$ 00KG=L?,5*@Q61?*\8MKV>JS307A'U M78 5$KOXY,%Z[LKH9Y6Z)+_*HUAIXV"%@4#%1##FY6_IY\*T\1PZ# MRI]>X!?<>ZHJL*>!#&W"RUQ EP4\7N1^1R2 ;NV0R55GNN\ T%1MTNJ*]KC M#DGE$-]R:]32B021'F73?^5KUK ,MRVKPD/:UVR]KI+W2G.U'_LVHUQKK^%H M?%.>K2@T(%CQ(@[YP_#8=3*PG#MKO8Z\Y)JSR^UL%*PP&*A8YTA^OKY6"6+< MRG\M(XPND/$ELMQ$188$)+Y;*DLK_WL(FZMML*# O@XI]P3JXRH0Y!YF;5/S MT,!VY6 94_"-R@RYE";N:NT7/G:ZKTM_=JL"*@0,5+ MRDUD93,IP8R2BT3NNOBO_&_C1;=:6WY;"UAD4F%!GU'4Z4*&!UN@ MH;K"M=_Z( ?XH3F2-BT?I>+B:SO KG);I,D) 0O4Q6T,C557>)^9*L.V^X$?F!^6\RVBWX()D522E]7C M7ZO)M\FRE)D3T5)5>$_^L[5[P3YVRER5@(_FZP15%6&X4AP,/F70-@)UWV7[ M)ZG*_X\K3^CGWM>>VQL;?&V-6QNL(% !CWWP;98( .!W[C!?YL%8"UC\\VY M;Y$FW[/P1(TL55=<*LE,=0'57RJ/ANUDZ3#\ZV&C!#)*M\_>(0(1V]DG5_:+N_O#JG^3 M0 4\YH9J=SKT!P#P.JD^L%CVZK);_V<9)@[L30XOGQ\":W4X'(V]KWZ5MD^#+8.W3RA-ZT/\_3!IF%ZUS-AR- M:?4)RY[VJ?;;EYP]6ZRHN(ZSG'M>3;X$*PA4P'-/;"0!0+V!9/%8\UZ&B0-[ MH;JB&_*^6VQ7A^[5D;FJ/J;5PE61#( ,\[RGK$#!/B/0 4 M!$9:_EE*D-#<8QQ^H;JB0P0LL(5: Q4RV)?!VK!"\^_#R7 T)@D%&OE241$9 MFU5X+"9."A3I:RM]YJS%!="E@PTP_/U1ZHD HDS15Z5%7@&](2[$;Q MN\+A)#3Q+5 1&=D;W1NK$/'>J\&*Z-O!VYIO,O"3*Z,:$*@ @+ 9"E@0K$!M MC%571%J#+P0LL$(3%161!"HT]_:^K#P"Z!ZX?C@1?E=Y$MC-.\JH E28[0?E_0OB"'?RQ55YQI[?\] MFTX^$[" '%K\T%"@(E+> NJ>P=I81;XOFI-1"%; 9^Z[]6.#]Z60/4D7&.YM M+=LX6%&*L_Q2VD*Q4,>NOBSRY7<) ("OXBR?,R\+^!W5%?YP 8O9='(L+4P1 MGB^'%K/I9-'$*Y= WE'E"3W8V^$EF@]2SZ1%&^";1[DO,2NH&>>23(>6;1VL MB"3S,)D+Z@?-TQ[,HB,$?./:]!\W?%\*62I[4G1@IV!%*(VL,31F+]]6'@'V1'6%?V;3B7L-/QJ8LX/774OF:M/] MJC4?ALY;>'^@F+0(TWQNI#F8"'O>S::3/M?=QEP3J.C67L&*Z+?#A(5469!= MA'7*MD_,%@; M =#\>^(&;1]7'@7:Y=8;W\^F$TW?)6V)7-?,UNW>WL&*4ISE+KOHSV04XAF7 MB?2&MD\ @&W%6:YQH"WW.S1%^X#2YTRTMI+V"SWF6)CSV/*!D.:#D4?:D&!# M<^7W,9(OT:5/4N6G[7JKJ;/*/=]S/]06K(A^.U1XB+.\)ZVA+)6J8WN/4DTQ MD,,F "V)O>0@:+-+0T!;*#-:[0,N,UQ.*D_H M054%-B+W,9FY[/TA8)SE#!A%DRZIKO"7M(4ZIM)<+??=2COH M ZZ]W01]O;$-S;\OKE5;O_(HT(PO9VNSZ<0%SS6?K6GXN[OWND^@PA^-!"M* M,I"DG&=!EI%]UQ*DN.!+#@"HDP0L?"_+I0T,&D5UA?_<$-G9=.)>TSOV/ZK< M2C5%%P>IFH,5-PQXQ3;DT%5S0BN][-&&+^W49].)^J0.UX%'04O?GNPUX8E& M@Q61M&^0>19O"%J8=;O4\DE3/SH @"*2!/'.X[\QV:5H ]45"LBL@V-I*01_ ME=44K@]XZ_N8X6CLLK0/*T_HP7T/N] <=#^1UFU $]R:X<^NM:2Q0+#/W_F4 M0(5_&@]6E,J@19SEW]$>RHPR2-&CY1, H UQEE]Z6L%PR[T0;:"Z0@^ILNC+ M+ OV/OXI,U>[/'#7/EB;UH?8A?8@%P-X4;<;F4O1[R)PWC1)./-Q'?1._F[P M3&O!BF7NET%F6OQ(3U>5;@A2 "ZXBKYHBCZ;SW[ $QFA\-;UJHK3 _H=0>Z ML^F$*G-_N/WG]UUGKLJ@WM/*$WIPP(.=R/=.<]49+LO9Q1%GUB\>^VIO)#&6=XG2 $ Z-B_X=&ZX8;[ M(MIDL+KB:#@:F^\#+KVGW\B^!^US69T_2LLG'UH^,%@;(=/\^W,H+=R 73Q* M\L*?)&@>1"MUJ6#P)5G]_XBS_-^L/ IO_-&'OXC,.7"E=.=%FO1EX:8YR\22 M>]D,SQF:#0#PA;LG%6ER%$71_]9Q\L4CPQ;1D4M9/Q\8^0 N0CC\E$#3^7 T MOI37?%;Y0ZB;NTY?=-SN:17-K61N0SE@0S-W/7\=KU;Z(H^E9;<%0NO:5513?QUE^ M+&V["%0 +P29[G;Y/Z##O].[G[9YQZ)+ABLKC@,H;JB)/,L!E)A?DV%>2,> M97AVUW,I*F1."X.U$3K-A[:G#-K&!F[D7/.-5%$$'>"21/4NJY+^:11%?U_V MD/"8%Y45J\C&WRV"KHHT^4Y^H=U/SU &F4^^1GI=P"CT-P, H$.!!GN0^M1! NJBN4D^ST@L0\V'V#ZXE4H*G]OS:0[,/7E8 MI0*=W#WLK>+/KF]]YA*V]BCG:HO0 Q/KN-:Y19JD'>S=W)EGC[V;#MX&*Y8M M!R[B$E0 $ T,I5 !9I$LF&L8U#V[*B@CD5Z)2K MKAB.QG-#K82^5%>$>! JE3(N6',AO=!IB[N=)]DK7OK>GD@"4YK[W;-O1"W< M=W4X&KO@XHG2=_2<8$7P[J6MT4("%+3'V\#2WJVM@ 6!"F54!"N>D\,!]W,A M51Q!<=<5S MDHTYEQ8C?3D0H]IBM1OI :[I=Z:OO!J*PUG4Z4KQ&8X+L/<\K^)"?.+R< MP#)WGY,UP&5#A[>?W$$J,RK@$\E,O3967>%:^%Q4G@F,9&BZZ]GE<#0^EFJ+ M'I7EOP4H)$BA\7JL>;#V_6PZ84^).LU;K(QMPD#.6Z"?.S_[+#]W2_]\H&*B M&;)W>\/>#<^I#U:L(H?RWRRBY M0!B_>R,^QH1Z_MQ+AO9/ !#?,^GU0]O=M M^W?@0>%[A,W4N3C3]CO"PE0968P.BC2YD@SM.A(6W,'8><<5B1JOL:Q%VG-A M['K%M?<9.2#^"5;;#FR^\"7# " >BRUB7SS M[-X<+9=ZNWLQ]U\ 6DG+J.5KG<\!C,>R,KQL7TL/< P-XM7 0K , X MJ][G/<"9?0 (!O$*P )0!C>>>5Y MY-U%4?0PFT[N*G\" /R]WO6B*.K+]>ZD\@=^=RO7N<5L.IE7GH5:!"L \ M)XOVGU_X6][,II-^Y=$ #4?CJRB*SEYXY3^0D;7:<#2^B*+H_11%[G?] M<-6?>86[SKD]P"77./UH P4 *#?Z7 T?A/ZXEPV.@1M )V.EO[6I^5_&([& MD61/SB5[DN %3))[V$ .['8YK%OG0+Y3[N?C<#2^ET.]J]ET\GG-OP._#%[X MVQRYX!;71F@E0?)SN5;MROV[;]W/<#3^($$+KF]*$:P "PX>*5S6P(]MWH M /#329E=/AR-'Y<.6LF>A'HNV4#NX2]5!=;)!08_NO_/X6CL@H 7?)?\);\? MKU77E$$N0-/O]K'__NN.G P'(W[!/%T M(E@! !@P]EP-#X//(LH]& -$()#.8AX/QR-KSEHA58=!"F>.Y#_[S,RD;VV M2<4HP0JH(JW-+EU$4_5G:1B[+Y/\/BA"L M L"/DK#HR"H%PG,UE ]'XSMIP^1;VT+W]_F)X)\_I$W.IHD8 M!"O@O37#XC^Y(?'[MFR2H(5K#?7NV5,$+)0A6 $ &#'08B+\>%HW%O1KQ9 M6 YD>/"<@U;X2#+?[W:\7SU%470319%KU_1C%$4_1%'TI]ET\E?EC\M*EL=3 M=_BW(L-X4R[XMY#6*NC6-@'8,ZY]\)D$WRZ?_15=FZ9:$PUFT\FE7 >79;)? M@ +,K +#E0H;5A81LJ7;\,)M.%B&\4$2WDIW8BJ5AF]6?DN]63^^1IY5]: MSP54[MSAWJK_7;1FVVJ)?H!K0.AQ]>R^OG*>Q(9!A;N79NRX_]WA:!P]J^)P MCQV_]._!#P0K ;#ETV9NSZ60>PN=<6Z4M[U.W,NQZ[_NX?+?<_TY9<70N/YL$ @_X'G5'*G&V M#=B>$ZR CR1@NUQ5=KTJ4"%^KCRRPG T=M?*\W77)PE8O%D*%!]*4A2/M;;9I:U,>M!Y7G@%:LF6@XO]O[WZ/ MVLBR/@#W6S7?F3<"O!'@#/!$ !N!695*7X>-P-X(EOFJ4FD@@H$(QD2P)H)W MB&"7#-ZZWL,@J]&]+?2O_SQ/E6MV6QBP:(GN^[OGG%1)\==4U;2+#0J)]%VVS$)0^>]S2]?MI557_RK7 C?>\Q6N'G[U& MVD]8 0#0/Z=#Z,L:-S\K;U" _D@MR*(UU3JAQ?-"JS[N[-V:044*#][OHRHR M0HO+>"T]UCZ@[FBA,H,]B.LBVF:YFNMRC59,-S&KY_E/>J]\ M6/J8TCR*Y6#D<^TC:!5A!0! /PWA9O7BC3WM@8Y:""W^7EBP>W:TT&(*]F(T MGEPV#"J>8A[0.HMW6Q$SB-['X.Z2X\46;>Q<[AKNL;#8FON[< B+Y^3#FJ%L MFMGS>>%/>J],[UM_7;H&6/F:B#91-PN'SH6O[2:L #HIX\#*'/6 @H&:CZ; M7L7@X.4=EJ])K5&N7CD.6Q<[?/_9X/,^1#7%P<*TJ+(X7UK(6^4T^LZS>[G MX;8PE^)8VR[:(F:O+,Z)KYN@-P^O9(V$% $!_]791 MX96;'V!@8K=DT\#BYT*;"-A8[-9MLFLXG;-I-L4?M4<.8#Z;7C0,+#X5%@39 M4&PT.U3R1J!A=?1;N6N;QX6 J[VDV-5YZKP%JO4"B]0.*M=>!=XL M*G=*G/KTL52"G(*[X?M;C]'DN$%0 W7=;6)P[?F5W4^?$C7QN ML>>IL,L0&(;2HL5I5&G!QN)W4ZGBK\FNW[;)_;ZM^G)MT2+GA>'LJZYO5AVO MA!7T7+KN_\=\-O4^U#/""@" ?B@MSO5A!V3I1O[JC27F0(_,9]/K0H!;%78P MPSJ:G$M7M2,M-Y]-TS#<^\)W:3%\>W+/Y5TF[,J=6R=O&$(,V[+<=NDM; MXGWH_I7?Z^^;5%0\$ZYVA[ " * '8G$NUPK@M N9DG*Z]O8E9/+ISU7L=!O/*^]Y;[D,M4 M.1'5$\OG\KH;L9;?J\RP:"EA!0! ?Y06YSK3+WM9[(8ZKCWPXN:5P9/ <*U< MW LG%EG9DE)E1:Y-3ZM%=45N(;Q2I;05N>?PJ<%@]MSCN<\-N[8X^V:C35/Q M?G2W<.CCFBT=%X/EIU?"%%I"6 $ T!]7A>J*=2_JVZ2T>ZIS+3: W8E%B+O" M%] 2@HW$[]1<>\*JP4)SVY5^OWH=;2ZWF:3)^9/[&:79(@(+#N7+PM?=QGO% M\FMEG:KJQ:__I?8HK2&L #HB5B<*]W4=JX=0(/V"/?1!@%@46DQPB(KFRKM M%"[-?.B"TG6%A? -1(O.7.5H<3$V*DL?:@^\\#/B4!9_#Q]M&IS%N?[+PJ'3 M)K,HXG5VLG"HZR%RKPDK #ZI52!<-G!UB>J*H"W*(45!L^RJ=(YU/G=NPT6 MPH\,<=Y(;A/)8[2^:2(7:I@MPD%$9=EBU7>NBJBISTN?,W?NK_JZPHH6$U8 M /1(+"KD6I\<%6Z,6R5NKC]FOJ?''K38 '8@*JYRK?%R%5O01&F1OB]5?X*_ MWLH*K07[R5NS*MH-V$% $#_ M]&G0=NE[+55= ,.672SN\!P?VJ&T6_V/VI%N$E;L0+3$RNO,N> ?O"D P#T2VH9,!I/[C.[ MAK_M0)K/IEVX6,^%%4_*N(&"+YGWPN1=CQ:4V;]LV-67>4I1P?@_M0?85"Y M>'S#^7.=>;]+.]K?1:@!>Y/.N=%XDN9,_!Q?\V0TGGR.P&$3Z1[AM_C[1_'_ MO_N<47%QMG#H9HW6:AR(R@H @'XJ!1&Y$* 5X@8CM^/P2ADW4%!:F+,CG$WD M!B,_UHY B%W@9YGGXRV[STL;.'+A".S29$.1"^TP.(<[-=/[]OO#E?QV-)]5RI?Q+P3-I2[!GO8X!HGMY'C.!9Q8>]B@]3?EK[NKYD*BS>)63!?EJJS?XE* M##I 6 $ T%^W4?*\REF+%UMR-_'5-H;S ?W78!>ER@K>JO3[LQ?S*MB^N/;* M;%@HHKBM<#B-C,@NY'T]T?CR57,L5@,*M(&)^=]AP@K M !Z*A;I2C>\K6L'$#?QJUH8)/=]&5H*0&]I-$JI87337> Y_Y^J?T4[-2* MP")=]Z=!W)_7#2TBI/@9CU59 >Q;+C"XVT)?_=RUW]&VV^[ NB*P^&FI"BA50WRJJNK?46EQ ML:H"/!U/[9Y&X\EUA!2?EJHITN?]JXJ*;C)@&P"@QU+/X]%X*!6"K8B;7<>9S;GR-DV8#C,:3Q\S7.2\$&K!S<9Z^ MBTU(R_Q5NE>)T.)_8Y[%76%0?!6/IX_[>_I[Z>^G:HW:1]$YVD ! M Q#JDCX/?,O_7SHE@#10WE5RX+D:@M]G %@&]Y[%EG3>:%Z=&MAQ7PV_5IH M!75A!AAM$]?YU\_W)!'PO?9>^]4]07$*P !B#ZPCYDRJ>/TZ"Z \^#*.WR MTU\9>(LOT3X"X)!R516[F,F5PHA_UH[^UTF:%Z!=#FT6@81JB8'1!@H 8#A* M.^AR+9AV*@9.YA83;]Q0 P!=%(.$SS+?^BXVBY0^Y\&N^P!6$58 Q$#&U\ MS/QK3R,T. 15%0! 7^6J*JI=7.?$)H^'V@,OVC*O#.!/P@H @&%IW<#%V&WX ML?; BWL#\P" #LM5,:064%]K1[ZNI1U]1YFOD6M?P'Y=C<:3?9P3VW(MZ *@!7)AQ4/,EMBEV\QP M[Z.X%O/[$F@%804 P,"DF^+1>'*3F1-Q%*V9]E%AD?L:3VZ>6^6D8]^O.2< M'%3,A,AMRMCY=4X*[D?CR57F^[APO06TA390 ##5*I8R.T"W(JX@<_V<-Y3 M=0< P"X)6P @!@@.:SZ=>JJNXS__+CT7BRZ\"B-%A; M"R@ H)-B%L2J]DO)W1XW9>3"BLJ@;: MA!4 ,-5"@-R+9HV,AI/WJ>=?)G/ M<;.''LX +M2"@!* <+6S&?3VVBON4II PG 7@@K &*FY<'S/_^E1=\:%V M=#M*-\5Z)P, 79:[UGG:9U@1G5%M$58-=P[ MN9_/IH8C P"=%#,@3C+?^^T!YG+EPHJJ$*X [,4/GF8 @.&:SZ;7H_$DM8,Z M6O$DI*&+[V/&Q;:HJNBFGX1( -!(Z5IGWU45W^:5C<:35%%[7'OPO\RM Y. M904 *79%=O>:9?[?(\I0*D=!0#HCMS"_U.TXCR$W#76T6@\R7W? #LGK MX*HP=/%CM#/8V&@\N5^KJA>J0U15+,B%%^#%62T%(EI ;OPWK,*[$.#=I>'; 'U3%@!M):P @" 9Z6;U]Q@ M[*R8>7&:^9B;"$P +HJ5U51M6%C1E2QWM4>>'&RK5EE .L25@ \,U\-OU2 M5=5]YMDXCAV#;U&JJC"K @#HK%C@/\M\_P\MVIA1JO!X\P85@$T(*P 6+3U MZHJ8=9';:7@?00D =(5J0);EKG6JEFW,*(45I7\+P$X(*P ^--\-DTWTH^9 M9^0D!F6OX[+0OUE5!7 HN?<[R"F%%6:E#$^I^K0-\RJ^B590N5EEJ9I68 'L MG; " (!EI99-I<>7Y6[>'R,@ =B57.]UN^/9E1\]L\,Q&D]2.'62^0??M7 V ME^H*H'6$%0 +$LWKT^UHR].FPY>C!D7Q[4'7AQ\T"30>[GW((!MR&W,J-I4 M5?%L/IN6KO?.HY4GP-X(*P ^$ZT!BB%"$VK*W(S+IZT@ ( >J!S847(?5]' MJBN ?1-6 #PFE)8\;&TVRYF6^1:(EQ', *P$]&:)<=P?V C,=LA-YOKKL77 M.Z7KO5(( [!5P@H &H:#%ZL"E4331[7 @K8M6RH"ALH+3Y_J!VAKTK5!ZVM M(IW/IE_3_+#: R\:M_X$V(8?/(L *R06CU]?/VA;RY'X\G5:[L%X\;VK/8W M7MRT<- DT#^E13;O0[Q)6N0=C2>>O(&+*M/0^[:I[[?&%7L:O[1@L556\]G< MDU8P:&HZAF&)C,=/M6. M=,NEL +8%VV@ #(*0W2KCT>NPQS/8[OY[.I/O' /I1:\7RM'8'FGC(?F9O9 M1'^4-F?TP7'+*T. 'E%9 0# 2BE4&(TG#YE%EW0#>S&?31*V-':SA:Z;Z\%M+Q+ZT/!R-)[E-!K?SV71P.^^CY>6JZZ.^N1A(, ,< MF,H* !*2@L0RU44N9O9QZ5@ V GHLHKUX?]OG8$UE,*N[)A65?$KOK3S)^A MRE61]LV0_JW 0DK #(BG#A,?,QIZ/QY%NKE51E45@<%%0 ^Z(%%+M6.H=* MYV!7E.8R#/6U-*0%_*/1>-)D/@? 1H05 TT;2Z(G?C_F1 ([!'P@IVK=3B MJ2]]_G.+U$]#G$,5FS1RFS/Z*'>-![ 59E8 -#$=0S37C6+XN-H/+G-]>Z. MGM;ZPP/[DEM@30SZ9U.]KZQH,)=AJ*^CTL+]74<#T4^U(R_.4GL]UW+ +@DK M H2C>FH_$D!18_9S[VM]J1[WVN'0'8@5A@S>UZ?NS+X&,.9SZ;?AV-)T^9 M(#^USGF?/J[V2'>4%N5O:T>&H12&7G;Q/2;FDYS5'GAQKJ4GL$O:0 $ T-0F M+9SN+ P">U1:8%55P;:4SJ6NM\[Q6EH2\[E6!53)0X>O>4I!Q&7M", 6"2L M &@D;KQOWOALF54![)/=X.Q+;\.*6)3/52@-=2-"J:JBL]<\\]GT-F:,K7(2 ME6L .R&L !@'6^Y 7\8XO!-X# :++ ^Q8(<;$/I7#J*<[*+2NT;!_#-A!0 ZUIGT66HBQG 32HJJ@, MAV4'2N?4<2S^=T)4#Y1VSP_U==3[%G-1#?M8>^!%.I\_U(X";(&P @" M32X MB5UD41#8B]%X\F.#2BYMZ=BZ".5+OQ<_C<:3][6C[71=&"#]-,2JR?CYG=0> M>/'4HPT:I="EZX/C@9825@ \!9-=H@._$Z0K76 MB@J0T\+W=]6#5D=O,:3!_<564&T_EX%N$E8 +"VV#GX5/A[MP-=S #V;#2> M7#=88-66CIV)^EUU+D9'%M2FM70F_>7F%'V M4'O@Q9'9%< N_.!9!0#@C=(.PUQ+"XN"P,Y%4/&QP=?1MH1=2W,>OA0J?$[3 M.3N?35MU/D:+HR:_MP?Y.HH@)S;2^?#/VM$7YZ[U@&T35@ \";S MV?2V9RT/@ Z)%B1IH>RLP7=]9U8%NY9VHT<;I=P";_)Q-)ZD_UZVH0(QAB4W M::/VRX!?1Z4J@CY>#]T6SN6S-(Q]/IO^47L$X(VT@0( *!38A?XUX9!Q:.J M"O9E/INFN2@W#;YJMWE48 M1 AQ5WO@>UI! 5LEK * 3TJ+A:#Q)B\'_*K1D>99FZYR;G\,^18NG7+__ M9VF&Q==H,;17\5I*"^R_-OBZ0W\=E7X^#S'CH8]*%2.7M2, &Q!6 T&JQ ML)IV=:>=OC^O\;U>]G@1D7;[T#"P2!4-OXW&D]M]55E$./*UX:R7%%1\&'BK MGU)E5I_G-I3"BN.H= /8"F$% K90656/W][^KJOK4H%7-HK_-9U/#7SF( MJ$)H&EA4T=+L_]+YOJO0(LVF&(TG:>;$;PTKDY*+(0=^\;,XK3WPO=[.[XKS MN-363)L]8&L,V 8 .#@8E'P72SP?FBP0+C*4RRP]G8!D6Y("[TQO+KI(/@J MJAW2 .XT*^!ZT_,X7E?GT:ZG:4!1+;1^&OI@^M)"_/T JDYN"U4X%]I! =LB MK )JX&HTG?>I7KCW0:N]C]_6^O%MS$37G,198_6QIA=B9?AZS5M9I89;" MC;/1>))"@R_1MNG;?W.S(Z(ESV+H=U+[H++GUD]>1\-N ?5-"LSB/%Q5V7:4 MJN $Q-^YB*"R+ZY5*K(OP@H *")MRQXM=F/?NHK'6U0U7!(OU15]3FWD N' M,I]-+R,$O,XL^K[FZ#FXB%9H*9"H(E!X#A-^W.)[]+VA]/\5P4\I2!W* GV3 MZ@IAQ8OC+8;P;3#T"BOVR,P* NBQ54_R4%H,ML-)FL?,\53W<;>';? X5 M3[<85/QC/IM^\#KZ4ZFUT=V GJNKVI'OI2H@FP" C0DK Z*+'&*+]3E]] MNB(M;L]GTS1#XJ>\=N1[@VF+$RW!2N=KZ?D"*-(& M"@ @"[9RN!A.*0(V-Z-QI/4/N?S@5K&W$?K-&'?DOBYY-IU/0WP/>BV,'?E M?SY4-C=W]1S0'$;KRF!7T;\#$JA46F&0^^D$&(TGCP49J1<-ICU ;"2L ( MH/V^1F_K5>Q@>W$=.[!7L>BY6NFYZYNAGPNY]Y1]^X] HC6\AQY8! G7S^UT M1N/)^ZJJ%O]4,53[-4\+/Z,O"X&?ZX3U9=\C!_R>=1Y#XE<92A!6NC;O&^\A :[$=55?\/06227C&YB_8 245.1*Y"8((! end XML 9 silk-20201110_htm.xml IDEA: XBRL DOCUMENT 0001397702 2020-11-10 2020-11-10 0001397702 false 8-K 2020-11-10 SILK ROAD MEDICAL, INC. DE 001-38847 20-8777622 1213 Innsbruck Drive Sunnyvale CA 94089 408 720-9002 false false false false false XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover Page	Nov. 10, 2020
Cover [Abstract]
Document Type	8-K
Document Period End Date	Nov. 10, 2020
Entity Registrant Name	SILK ROAD MEDICAL, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38847
Entity Tax Identification Number	20-8777622
Entity Address, Address Line One	1213 Innsbruck Drive
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94089
City Area Code	408
Local Phone Number	720-9002
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001397702
Amendment Flag	false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .R :E$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #L@&I1NLX4N^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2@,Q$(=?17+?G62+%<(VEXHG!<&"XBTDTS:X^4,RLMNW=W=MMX@^@,?,_/+- M-S"M2=+$C,\Y)LSDL-P,O@M%FK1A1Z(D 8HYHM>E'A-A;.YC]IK&9SY TN9# M'Q :SM?@D;35I&$"5FDA,M5:(TU&33&?\=8L^/29NQEF#6"''@,5$+4 IJ:) MZ31T+5P!$XPP^_)=0+L0Y^J?V+D#[)P'MZ?)G7K5PH MI(/!\5=QDDX)-^PR^76UO=\],-7PAE="5(+OQ%KR.]G621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M .R :E'#^H]UP0, &4. 8 >&PO=V]R:W-H965T&UL ME9==;^(X%(:O9W^%E>NV^8 V, (D"G07]0N5SHZTJ[TPB0&KB9VU'2C_?H\# M)*PFG- ;8B<^+X_/L=_$O:U4'WK-F"&?:2)TWUD;DWUW71VM64KUC$.>AE=L3DS/[*9@IY;JL0\94)S*8ABR[XS]+_?!T5 ,>)/ MSK;ZI$WL5!92?MC.-.X[GB5B"8N,E:!PV; 12Q*K!!S_'D2=\C]MX&G[J/Y0 M3!XFLZ":C63RD\=FW79/;/]AA0K=6+Y*)+G[)=C^VW79(E&LC MTT,P$*1<[*_T\Y"(DX#@7$!P" @*[OT?%91C:NB@I^26*#L:U&RCF&H1#7!< MV*K,C8*G'.+,8"0W3)$9%*#G&M"S=]WH$'N_CPW.Q+[(S0WQO2L2>('W_W 7 M,$J6H&0)"KT6RO+W<*&-@FK]@TBV2LE6(=D^(SF640YKR)#W758[0SR\<_V( M0+1+B/9E$#.FN(S)1,0$BE7+@RL=,_[;MV\-.;\MV6Y1Q8DPW.S(&UMQFW6 M?*%I+1FN,Y\^/9*WU^&8/$_&T]'PZ8I,7T8W".%=27AW">%41%)E4E&[F:_( MW$ "B51D)'-AU ZN<2TV+CZ>((1A21A>0OC $T9>\G3!5!T(KN%Y_G6KTVF' M"$^GY.E*:7UU M;) G&$=>16T5<44_\%NP0(1>J#SZ(&,%1H^ ^EYECMZ74$>V!XON76Y%K5_B MACLK_V'!1,Q?+6\+I=GZH?K-9)5 MIN_C'OT+V53K',@: 7'91L#*]OV+?'^2,K6R]?P=%,S:+K:,BETM&B[8A!94 M/A]7"!LTER3PX-]@#V3&U9-$G8$H2\FQ"VN-J?:?8=([/B'+&0!DXE17,-YT"F M[ !XOI32'#OV:%*>+ ?_ 5!+ P04 " #L@&I1@ZFE ]0! R!@ #0 M 'AL+W-T>6QE1'9!20(J+ @J"SL/OG:22M+0 M-SN5,=FOMSN=V[@,J ^B+Y,ZIZI/G;Y.UN,DX:D#0#(JJ?N<=HCV+6-]U8'B M_2MC0?M,8YSBZ*%K66\=\+H/@Y1DZ>ETSQ07FA:9'M2#PIY49M"8TQ-E1=88 MO3.O:21\*5= +ESF] .7HG1BKN5*R"G2:2 J(XTCZ*U 3I/ ],\QG4047"XZ M2FCC LEBA_A;+N4_)5;4>RBDW RF-!)%9CDB./W@P5P\DR]29(G/D_4.6\>G M)+VC^X#YXYN4QM7@MC8)7:DBD] $.TZT7?BBL2PD$8WR02UX:S2?/:PCEL#+ M5B#E4]C"K\V5]MB0N!_9$LL>)B\/W@ M9Z-G_&TP"(\.&C'.>&RV_K?4D]OJW%HYO9.BU0KBW'^Y89'Q=1SIC!//OELX M*94GP%%R 8>B.C+?';=G&'$]36-SVW/Z'WK^N^O<@@;'Y=&T/_K_\BK_CF.V MW)[#%;VZH!M+PD.8TR_A?96[!U(.0J+0"^I$78-^<4^]//+2/^!7^KZ^AH8/ M$L];,J=[_!EJ,:@W6]5C6)>E:H\_A?*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5 MN %(MB6/:(7->=I3W; M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II% MR=.B':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/4 M6PQFN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO40 M9.B1P74&0ZRQB28)UD-N5G0&3K;V"%TH?653#@%%G=W4Q7/4 6_*P>-HK(0* M Y1OJA65UY**+2?=T>M,[Q\FCUI&Z]Q*N??P2K8<&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_ M[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ M0=@S9)[NF:*'3^ 5!+ P04 M " #L@&I199!YDAD! #/ P $P %M#;VYT96YT7U1Y<&5S72YX;6RM MDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C> MO,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0 MP1-XJBA[E.O5,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH% M.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D M(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S6 M3AI_YHOA/UY_ 5!+ 0(4 Q0 ( .R :E$'04UB@0 +$ 0 M " 0 !D;V-0&UL4$L! A0#% @ [(!J4;K. M%+ON *P( !$ ( !KP &1O8U!R;W!S+V-O&UL M4$L! A0#% @ [(!J49E&PO=V]R:W-H965T&UL M4$L! A0#% @ [(!J48.II0/4 0 ,@8 T ( !! P M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! M A0#% @ [(!J420>FZ*M ^ $ !H ( !4! 'AL M+U]R96QS+W=O9(9 M 0 SP, !, ( !-1$ %M#;VYT96YT7U1Y<&5S72YX;6Q0 52P4& D "0 ^ @ ?Q( end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://silkroadmed.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports silk-20201110.htm silk-20201110.xsd silk-20201110_cal.xml silk-20201110_def.xml silk-20201110_lab.xml silk-20201110_pre.xml silkq32020earningspressrel.htm http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "silk-20201110.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "silk-20201110_cal.xml" ] }, "definitionLink": { "local": [ "silk-20201110_def.xml" ] }, "inline": { "local": [ "silk-20201110.htm" ] }, "labelLink": { "local": [ "silk-20201110_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "silk-20201110_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "silk-20201110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 20, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "silk", "nsuri": "http://silkroadmed.com/20201110", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "silk-20201110.htm", "contextRef": "i5da3b02332594b929431aa1821847d5f_D20201110-20201110", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://silkroadmed.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "silk-20201110.htm", "contextRef": "i5da3b02332594b929431aa1821847d5f_D20201110-20201110", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://silkroadmed.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r3": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001397702-20-000042-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001397702-20-000042-xbrl.zip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